Drug-resistant Trials

Trials for Gleevec, Sutent, Stivarga resistant GIST

The trials listed below are for Gleevec-resistant GIST (in most cases, Sutent-resistant as well). Click on the hyperlinks for more details about each trial. You will also have the opportunity to access trial site data later. Trials are sorted so that trials that are only for GIST appear first. Trials are also sorted so that trials in later phases sort higher on the list. Phase I trials are included in this listing. Note: The LRG uses ClinicalTrials.gov and other sources to compile the LRG Clinical Trials database. Click on the name (title) to see the trial details in the LRG database. Click on the NCT link (below) to see the trial details in ClinicalTrials.gov. The drug name listed will be the most advanced available; i.e., brand name first or generic name and if neither of those are available, IND.

21 trials found
A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)
Phase:  1/2
Category:   KIT/PDGFRA inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
START Midwest Grand Rapids MI USA
HonorHealth Virginia Piper Cancer Center Scottsdale AZ USA
University of Miami, Sylvester Comprehensive Cancer Center Miami FL USA
Dana Farber Cancer Institute Boston MA USA
 


A Study of DCC-3116 in Combination with Anticancer Therapies in Participants with Advanced Malignancies
Phase:  1/2
Category:   ULK1/2 inhibitor + KIT inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
START Midwest Michigan, PC Grand Rapids MI USA
University of Miami, Sylvester Comprehensive Cancer Center Miami FL USA
New York University New York NY USA
Memorial Sloan Kettering New York NY USA
Cleveland Clinic Taussig Cancer Center Cleveland OH USA
Oregon Health & Science University Portland OR USA
Ronald Reagan UCLA Medical Center Los Angeles CA USA
Fox Chase Cancer Center Philadelphia PA USA
Washington University School of Medicine St. Louis MO USA
USC-Norris Cancer Center Los Angeles CA USA
 


(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
Phase:  3
Category:   KIT inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Mid Florida Hematology and Oncology Center Orange City FL USA
University of Toledo Medical Center Toledo OH USA
City of Hope Duarte CA USA
Medstar Hospital Washington Washington DC USA
University of Miami, Sylvester Comprehensive Cancer Center Miami FL USA
Orlando Health UF Health Cancer Center Orlando FL USA
University of Michigan Ann Arbor MI USA
Vanderbilt-Ingram Cancer Center Nashville TN USA
MD Anderson Cancer Center Houston TX USA
Dana Farber Cancer Institute Boston MA USA
Washington University School of Medicine St. Louis MO USA
Fox Chase Cancer Center Philadelphia PA USA
Robert Lurie Comp. Cancer Center Northwestern University Hospital Chicago IL USA
UAB Comprehensive Cancer Center Birmingham AL USA
Mayo Clinic in Arizona Scottsdale AZ USA
UCLA Hematology/Oncology Santa Monica CA USA
Moores Cancer Center/UCSD Medical center La Jolla CA USA
Mayo Clinic, Jacksonville Jacksonville FL USA
H. Lee Moffit Cancer Center Tampa FL USA
University of Iowa Hospitals and Clinics Iowa City IA USA
Mayo Clinic, Rochester Rochester MN USA
Roswell Park Cancer Institute Buffalo NY USA
Memorial Sloan Kettering New York NY USA
Duke University Durham NC USA
Knight Cancer Institute at Oregon Health Sciences University (OHSU) Portland OR USA
University of Pittsburgh Cancer Institute Pittsburgh PA USA
University of Washington - Seattle Cancer Care Alliance Seattle WA USA
Carbone Cancer Center, University of Wisconsin Madison WI USA
Sir Charles Gairdner Hospital Nedlands Western Australia Australia
Princess Margaret Hospital Toronto ON Canada
Arhus University Hospital Arhus Denmark
Institut Bergonie Bordeaux Gironde France
Centre Oscar Lambret - Lille Lille Nord France
Hopital Edouard Herriot Lyon France
Hospital de La Timone Marseille France
Centre Eugene Marquis Rennes Isle-et-Vilane France
St. Herblain Saint-Herblain Loire Atlantique France
Centre Hospitalier Universitaire Toulouse Purpan Toulouse Haut-Garonne France
Institut Gustave Roussy Villejuif Val de Narne France
Helios Klinikum Bad Saarow Bad Saarow Germany
Helios Klinikum Berlin-Buch Berlin Germany
Medizinische Hochshule Hannover Hannover Germany
Medical Oncology University Debrecen Debrecen Hungary
National Cancer Centre Goyang Republic of Korea
Seoul National University Hospital Seoul Republic of Korea
Asan Medical center Seoul Songpa-gu Republic of Korea
Samsung Medical Center Seoul Republic of Korea
University Medical Center Groningen Groningen Netherlands
University Medical Center Nijmegen st Raboud Nijmegen Gelderland Netherlands
Dept of Oncology, Haukeland University Hospital Bergen Norway
Oslo University Hospital Oslo Norway
Hospital Universitari Vall d'Hebrón Barcelona Spain
Hospital Universitario Clínico San Carlos Madrid Spain
Fundacion Jimenez Diaz Madrid Spain
Dept. of Oncology, Skane University Lund Sweden
Karolinska University Hospital Solna Sweden
Taipei Veterans General Hospital Taipei Taiwan
China Medical University Hospital Taichung Taiwan
University of Colorado Aurora CO USA
University of Arizona Cancer Center Tucson AZ USA
Ubiversity of California San Francisco San Francisco CA USA
University ofKansas Cancer Center Kansas City KS USA
University of Tennessee Knoxville TN USA
Bankstown-Lidcombe Hospital Bankstown Australia
CEPHO-Centro de Estudos e Pesquisas de Hematologia e Oncologia Sao Paulo Sao Paulo Brazil
Centro de Oncologia de Precision, Iniversidad Mayor Santiago Chile
Humanity & Health Clinical Trial Centre Central Hong Kong China
Hong Kong United Oncology Centre Jordan Hong Kong China
Prince of Wales Hospital Sha Tin Hong Kong China
Korea University Guro Hospital Seoul Republic of Korea
Hospital Clinico de Santiago de Compostela Santiago de Compostela Spain
National Taiwan University Hospital New Taipei City Taiwan
Azienda Ospedaliera Universitaria Careggi Rozzano Italy
Ohio State University Comprehensive Cancer Center Columbus OH USA
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo Italy
Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital Amsterdam Netherlands
Hospital 12 octobre Madrid Spain
Instituto Alaxender Fleming Buenos Aires Argentina
Azianda Ospedaliera Universitaria Integrata Verona-Ospedale Borgo Trento Verona Italy
Centrum Onkologii im. Prof. Franciszka Lukaszczyka Bydgoszcz Poland
Tom Baker Cancer Center Calgary AB Canada
Azienda Ospedaliera Spedali Civili di Brescia-Oncology Brescia Italy
AOUC Azienda Ospedaliero - Universitaria Careggi Firenze Italy
Istituto Romagnolo per lo Studio dei Tumors "Dino Amadori" Medola Italy
Erasmus Medical center Rotterdam Netherlands
Hospital Virgen del Rocio Sevilla Spain
University College Hospital London UK
Royal Marsden Hospital - Chelsea London UK
lnstituto Nacional de Cancer - INCA Rio De Janeiro Brazil
Centro de Oncologia de Precision, Universidad Mayor Instituto Oncologico FALP Santiago Chile
Masarykuv onkologicky ustav Brno Czechia
Policlinico Universitario Campus Bio-Medico Roma Italy
I Can Oncology Center SA De CV Monterrey Mexico
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Oddzial w Gliwicach, Oddzial Chemioterapii Dziennej Gliwice Poland
Nebraska Methodist Hospital Omaha NB USA
Cleveland Clinic Taussig Cancer Center Cleveland OH USA
UNICAMP - Hospital das Clinicas Campinas Brazil
Cross Cancer Institute Edmonton AB Canada
Maisonneuve-Rosemont Hospital Montreal QC Canada
Institut Bergonie Bordeaux Gironde France
Universitatsklinikum Essen, West Germany Cancer Center Essen Germany
Universistatsklinikum Mannheim Mannheim Germany
Istituto Nazionale Dei Tumori Milan Italy
Instituto Europeo di Oncologia Milano Italy
Marie Sklodowska-Curie Memorial Cancer Center Warsaw Poland
Hospital San Pau Barcelona Spain
Hospital Universitairio Virgen de la Arrixaca Murcia Spain
Hospital Universitario Gregorio Maranon Madrid Spain
hospital Universitario Miguel Servet Zaragosa Spain
Chang Gung Memorial Hospital Linkou Taoyuan County Taiwan
The Beatson Institute Glasgow UK
Guy's Hospital London UK
Christie Hospital NHS Trust Manchester Lancashire UK
Instituto Oncologico de Cordoba (IONC) Cordoba Argentina
Fakultni nemocnice Hradec Kralove Hradec Kralove Czechia
Fakultni nemocnice Olomouc - Oncology clinic Olomouc Czechia
IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola Bologna Italy
IRCCS La Fondazione e l'Istituto di Candiolo Candiolo Italy
Centro de Investigacion Medica Aquascalientes (CIMA) Aguascalientes Mexico
Oaxaca Site Management Organization S.C. Oaxaca Mexico
Szpital Specjalistyczny w Brzozowie Brzozow Poland
Institut Catala d'Oncologia - L'Hospitalet Barcelona Spain
Chang Gung Memorial Hospital - Kaohsiung Branch Kaohsiung Taiwan
Sheffield Teaching Hospital Sheffield UK
Cambridge University Hospitals Cambridge UK
Centro Riferimento Oncologico - Aviano Aviano Italy
Cambridge University Hospitals Cambridge UK
Sheffield Teaching Hospital Sheffield UK
Centro Riferimento Oncologico - Aviano Aviano Italy
 


A Study of Olverembatinib in SDH-deficient GIST. (POLARIS-3)
Phase:  3
Category:   SDH-directed
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Sun-Yat Sen University Cancer Center Guangzhou Guandong China
Alfred Health (Medical Oncology) Melbourne Melbourne VIC Australia
 


A Phase 3 Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib (INSIGHT)
Phase:  3
Category:   KIT/PDGFRA inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Oregon Health & Science University Portland OR USA
Princess Margaret Hospital Toronto ON Canada
Cleveland Clinic Taussig Cancer Center Cleveland OH USA
Dana Farber Cancer Institute Boston MA USA
Memorial Sloan Kettering New York NY USA
Moores Cancer Center/UCSD Medical center La Jolla CA USA
Yale University School of Medicine New Haven CT USA
Mayo Clinic, Jacksonville Jacksonville FL USA
Johns Hopkins Sidney Kimmel Comp Cancer Center Baltimore MD USA
Masonic Cancer Center at University of Minnesota Minneapolis MN USA
Mayo Clinic, Rochester Rochester MN USA
Monter Cancer Center - Northwell Health Hyde Park NY USA
Ohio State University Comprehensive Cancer Center Columbus OH USA
Oklahoma University Cancer Institute Oklahoma City OK USA
MD Anderson Cancer Center Houston TX USA
University of Washington - Seattle Cancer Care Alliance Seattle WA USA
Alfred Health (Medical Oncology) Melbourne Melbourne VIC Australia
Centro de Pesquisas Oncologicas Florianopolis Brazil
lnstituto Nacional de Cancer - INCA Rio De Janeiro Brazil
Juravinski Cancer Center Hamilton ON Canada
McGill University Montreal QC Canada
Clinica San Carlos de Apoquindo Red Salud UC Christs Las Condes Chile
Centre Léon Bérard Lyon Rhone France
Institut Gustave Roussy Villejuif Val de Narne France
Helios Klinikum Berlin-Buch Berlin Germany
Site name unknown Napoli 80131 Napoli Italy
IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola Bologna Italy
Istituto Nazionale Dei Tumori Milan Italy
IOV - Instituto Oncologico Veneto IRCCS Padova Italy
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo Italy
Policlinico Universitario Campus Bio-Medico Roma Italy
Asan Medical center Seoul Songpa-gu Republic of Korea
Samsung Medical Center Seoul Republic of Korea
University Medical Center Groningen Groningen Netherlands
Leiden University Leiden Netherlands
Centrum Onkologii - Instytut Im. Sklodowskiej-Curie w Warszawie Warsaw Poland
Hospital Alvaro Cunqueiro, Vigo Vigo Spain
Hospital San Pau Barcelona Spain
Hospital Vall d'Hebron Barcelona Spain
Fundación Instituto Valenciano de Oncología Valencia Spain
China Medical University Hospital Taichung Taiwan
Taipei Veterans General Hospital Taipei Taiwan
St. James University Hospital Leeds UK
Royal Marsden Hospital - Chelsea London UK
Centro de Investigacion Medica Aquascalientes (CIMA) Aguascalientes Mexico
Oaxaca Site Management Organization S.C. Oaxaca Mexico
University of Miami, Sylvester Comprehensive Cancer Center Miami FL USA
Boston Medical Center Boston MA USA
Prince of Wales Hospital Randwick New South Wales Australia
Hospital de Cancer de Barretos - Fundacao Pio XII Barettos Sao Paulo Brazil
Hospital Sirio-Libanes Sao Paulo Sao Paulo Brazil
Hospital 9 de Julho Sao Paulo Sao Paulo Brazil
AC Camargo Câncer Center Sao Paulo Brazil
H. Lee Moffit Cancer Center Tampa FL USA
University of Pittsburgh Cancer Institute Pittsburgh PA USA
Centro de Oncologia de Precision, Universidad Mayor Instituto Oncologico FALP Santiago Chile
Centre George Francois Leclerc Dijon Bourgogne-Franche-Comté France
Centre Eugene Marquis Rennes Isle-et-Vilane France
Site name unknown, Bordeaux Bordeaux France
Universitatsklinikum Essen, West Germany Cancer Center Essen Germany
Seoul National University Hospital Seoul Republic of Korea
Oslo University Hospital Oslo Norway
Fundacion Jimenez Diaz Madrid Spain
Hospital Universitario Gregorio Maranon Madrid Spain
National Chen Kung University Hospital Tainan Taiwan
Arthur J. E. Child Comprehensive Cancer Center Calgary Alberta Canada
 


SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST
Phase:  2
Category:   KIT inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
University of Miami, Sylvester Comprehensive Cancer Center Miami FL USA
Dana Farber Cancer Institute Boston MA USA
Oregon Health & Science University Portland OR USA
Fox Chase Cancer Center Philadelphia PA USA
 


ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST
Phase:  2
Category:   KIT/PDGFRA/VEGF inhibitors
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
University of Miami, Sylvester Comprehensive Cancer Center Miami FL USA
 


A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments (ATEZOGIST)
Phase:  2
Category:   KIT/PDGFRA inhibitor + PD-L1 inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Centre Léon Bérard Lyon Rhone France
La Timone University Hospital, Medical Oncology Unit Marseille Bouches du Rhone France
Hopital Robert Debre Reims Marne France
Institut Gustave Roussy Villejuif Val de Narne France
ICANS Institut de Cancérologie Strasbourg Strasbourg France
Institut Bergonie Bordeaux Gironde France
Centre Oscar Lambret - Lille Lille Nord France
Centre Antoine LACASSAGNE Nice Alpes-Martines France
CHU Poitiers - Hospital la Miletrie Poitiers Vienne France
Centre Eugene Marquis Rennes Isle-et-Vilane France
St. Herblain Saint-Herblain Loire Atlantique France
Chru Tours Tours France
 


Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib.
Phase:  2
Category:   Tubulin inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Asan Medical center Seoul Songpa-gu Republic of Korea
 


Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.
Phase:  2
Category:   KIT/PDGFRA inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
MD Anderson Cancer Center Houston TX USA
 


A Study of Regorafenib Combined with Envafolimab for Metastatic Gastrointestinal Stromal Tumors with Kit Gene Exon 17 Mutation That Failed Standard Treatment
Phase:  2
Category:   PD-L1 Antibody + KIT/PDGFRA inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Peking University School of Oncology Beijing China
 


Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor
Phase:  2
Category:   VEGFR inhibitor + Microtubule stabilizer
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Asan Medical center Seoul Songpa-gu Republic of Korea
 


The Efficacy and Safety of Temozolomide in SDH-deficient GIST (GIST)
Phase:  2
Category:   SDH-directed
Conditions:  

Site
City
State
Country
Asan Medical center Seoul Songpa-gu Republic of Korea
 


A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) [Study ID: StrateGIST1]
Phase:  1
Category:   KIT/PDGFRA inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Dana Farber Cancer Institute Boston MA USA
Fox Chase Cancer Center Philadelphia PA USA
University of Miami, Sylvester Comprehensive Cancer Center Miami FL USA
Knight Cancer Institute at Oregon Health Sciences University (OHSU) Portland OR USA
MD Anderson Cancer Center Houston TX USA
Universitair Ziekenhuis Gasthuisberg Leuven Belgium
Helios Klinikum Berlin-Buch Berlin Germany
Universitatsklinikum Essen, West Germany Cancer Center Essen Germany
Hospital Vall d'Hebron Barcelona Spain
Memorial Sloan Kettering New York NY USA
Beijing Cancer Hospital Beijing Beijing China
Sun Yat-sen University Cancer Center Guangzhou Guandong China
Union Hospital Medical College Huazhong University of Science and Technology Wuhan Hubei China
Institut Bergonie Bordeaux Gironde France
Centre Léon Bérard Lyon Rhone France
La Timone University Hospital, Medical Oncology Unit Marseille Bouches du Rhone France
Institut Gustave Roussy Villejuif Val de Narne France
Zhongshan Hospital, Fudan University Shanghai Shanghai Sheng China
Istituto Nazionale Dei Tumori Milan Italy
Seoul National University Hospital Seoul Republic of Korea
Asan Medical center Seoul Songpa-gu Republic of Korea
Yonsei University Health System Seoul Republic of Korea
Samsung Medical Center Seoul Republic of Korea
Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital Amsterdam Netherlands
Erasmus Medical center Rotterdam Netherlands
Royal Marsden Hospital - Chelsea London UK
Seoul National University Hospital (SNUH) Seoul Republic of Korea
 


A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)
Phase:  1
Category:   HSP90 inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Alfred Health (Medical Oncology) Melbourne Melbourne VIC Australia
Flinders Medical Centre Bedford Park South Australia Australia
Beijing Cancer Hospital Beijing Beijing China
Fudan University Shanghai Cancer Center Shanghai China
National Cancer Center Hospital East Chiba Japan
Hokkaido University Hospital Sapporo Hokkaido Japan
Kumamoto University Hospital Kumamoto Japan
Osaka University Hospital Osaka Japan
The Cancer Institute Hospital of the Japanese Foundation Ariake Koto Japan
The Cancer Institute/National University Hospital Singapore Singapore
Kaohsiung Chang Gung Memorial Hospital Taichung Taiwan
Chang Gung Memorial Hospital Linkou Taoyuan County Taiwan
Taipei Veterans General Hospital Taipei Taiwan
National Cancer Center Hospital Chuo-ku Tokyo Japan
 


A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE)
Phase:  1/2
Category:   Kit inhibitor + PD-L1 Inhibitor
Conditions:  Solid Tumors

Site
City
State
Country
Institut Bergonie Bordeaux Gironde France
Centre Régional de Lutte contre le Cancer de Montpellier Montpellier Herault France
Institut Claudius Regaud Toulouse France
Hopital Morvan Brest France
Centre Léon Bérard Lyon Rhone France
Instituit Curie Paris France
Institut Gustave Roussy Villejuif Val de Narne France
 


Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Phase:  2
Category:   SDH-directed
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Cedars-Sinai Outpatient Cancer Center Los Angeles CA USA
University of Iowa Hospitals and Clinics Iowa City IA USA
University of Michigan Ann Arbor MI USA
Washington University School of Medicine St. Louis MO USA
Mount Sinai School of Medicine New York NY USA
Abramson Cancer Center - University of Pennsylvania Philadelphia PA USA
Vanderbilt-Ingram Cancer Center Nashville TN USA
MD Anderson Cancer Center Houston TX USA
Peking University First Hospital-Urology Beijing Beijing China
Prince of Wales Hospital Randwick New South Wales Australia
Royal Melbourne Hospital Parkville Victoria Australia
Arthur J. E. Child Comprehensive Cancer Center Calgary Alberta Canada
Princess Margaret Hospital Toronto ON Canada
CHRU Strasbourg - Hôpital Hautepierre Strasbourg France
Institut Paoli-Calmette Marseille Bouches du Rhone France
Institut Gustave Roussy Villejuif Val de Narne France
Hopital Edouard Herriot Lyon France
University of Freiburg - Tumor Biology Center Freiburg Germany
Charite Comprehensive Cancer Center (CCCC) Berlin Germany
Instituto Europeo di Oncologia Milano Italy
Hokkaido University Hospital Sapporo Hokkaido Japan
Universitair Medisch Centrum Utrecht Netherlands
National Cancer Center Singapore Singapore
Hospital 12 octobre Madrid Spain
Hospital Vall d'Hebron Barcelona Spain
Dept. of Oncology, Skane University Lund Sweden
Dept. of Oncology, Academic Hospital Uppsala Sweden
Beatson West of Scotland Cancer Centre Glasgow UK
Johns Hopkins Sidney Kimmel Comp Cancer Center Baltimore MD USA
Sheba Medical Center Ramat Israel
Azianda Ospedaliera Universitaria Integrata Verona-Ospedale Borgo Trento Verona Italy
National Cancer Center Hospital Chuo-ku Tokyo Japan
Karolinska University Hospital Solna Sweden
Dept. of Oncology, Sahlgrenska University Hospital Gothenburg Sweden
Cambridge University Hospitals Cambridge UK
Massachusetts General Hospital Boston MA USA
Renji Hospital Shanghai Jiao Tong University School of Medicine Shanghai Shanghai China
West China Hospital of Sichuan University Cheng Du Sichaun China
Rigshospitalet-Department of Endocrinology Copenhagen Hovedstaden Denmark
Odense C, Universitetshospital Odense Syddanmark Denmark
Hôpitaux Universitaires Paris Sud - Hôpital Bicêtre Paris France
Hopitaux Universitaires Paris Centre-Hopital Cochin Paris France
Klinikum der Ludwig-Maximilians-Universitaet Muenchen Munchen Bayern Germany
Comprehensive Cancer Center Mainfranken Wurzburg Bayern Germany
Semmelweis University-Belgyógyászati és Onkológiai Klinika Hematológia Osztály Budapest Hungary
University of Naples Federico II Naples Campania Italy
Ospedale San Raffaele-Oncologia Medica Milano Lombardia Italy
Azienda Ospedaliera Spedali Civili di Brescia-Oncology Brescia Italy
Yokohama City University Hospital Yokohama Kanagawa Japan
Kochi Medical School Hospital Nankoku Kochi Japan
Kyoto University Hospital Kyoto Japan
Tokyo Women's Medical University Adachi Medical Center Tokyo Japan
Hospital Universitario Central de Asturias-Medical Oncology Oviedo Asturias Spain
MD Anderson Cancer Center-Oncology Madrid Madrid Spain
Ege University Medicine of Faculty Bornova Izmir Turkey
Hacettepe Universitesi-oncology hospital Ankara Turkey
Ankara Bilkent Şehir Hastanesi. Ankara Turkey
Istanbul Universitesi Cerrahpasa-Medical Oncology Istanbul Turkey
Royal Free Hospital London England UK
Hammersmith Hospital-Medical Oncology London UK
National Cancer Institute Bethesda MD USA
Tel-Aviv Sourasky Medical Center Tel Aviv Israel
Sun Yat-sen University Cancer Center Guangzhou Guandong China
Universitaetsklinikum Duesseldorf-Gastroenterology, Hepatology and Infectiology Düsseldorf Nordheim-Westfalen Germany
Rigshospitalet Copenhagen Hovedstaden Denmark
Centro de Oncologia de Precision, Universidad Mayor Instituto Oncologico FALP Santiago Chile
FALP Arturo Lopez Perez Foundation Santiago Chile
University of Freiburg - Tumor Biology Center Freiburg Germany
Seoul National University Hospital (SNUH) Seoul Republic of Korea
Asan Medical center Seoul Songpa-gu Republic of Korea
Oslo University Hospital Oslo Norway
Baskent University Adana Training Hospital Uuregir Adna Turkey
 


A Study of HQP1351 (Olverembatinib) in Patients With GIST or Other Solid Tumors
Phase:  1
Category:   SDH-directed
Conditions:  Solid Tumors

Site
City
State
Country
Sun-Yat Sen University Cancer Center Guangzhou Guandong China
Guangdong General Hospital Guangzhou Guangdong China
Union Hospital Medical College Huazhong University of Science and Technology Wuhan Hubei China
Chinese PLA General Hospital Beijing China
Fudan University Shanghai Cancer Center Shanghai China
Henan cancer hospital Zhengzhou Henan China
 


A Study of NB003 in Patients With Advanced Malignancies
Phase:  1
Category:   KIT/PDGFRA inhibitor
Conditions:  Solid Tumors

Site
City
State
Country
Memorial Sloan Kettering New York NY USA
Peking University School of Oncology Beijing China
Fudan University Shanghai Cancer Center Shanghai China
Stanford University Palo Alto CA USA
Dana Farber Cancer Institute Boston MA USA
Oregon Health & Science University Portland OR USA
MD Anderson Cancer Center Houston TX USA
Beijing Cancer Hospital Beijing Beijing China
Centre Léon Bérard Lyon Rhone France
Institut Gustave Roussy Villejuif Val de Narne France
Asan Medical center Seoul Songpa-gu Republic of Korea
Samsung Medical Center Seoul Republic of Korea
Hospital Vall d'Hebron Barcelona Spain
Fundacion Jimenez Diaz Madrid Spain
Royal Marsden Hospital - Chelsea London UK
Sun-Yat Sen University Cancer Center Guangzhou Guandong China
Xiangya Hospital Central South University Changsha Hunan China
Union Hospital Medical College Huazhong University of Science and Technology Wuhan Hubei China
Renji Hospital Shanghai Jiao Tong University School of Medicine Shanghai Shanghai China
West China Hospital of Sichuan University Cheng Du Sichaun China
The Second Hospital of Anhui Medical University Hefei Anhui China
Peking University People's Hospital Beijing Beijing China
The First Affiliated Hospital of Chongqing Medical University Chongqing Chongqing China
Fujian Cancer Hospital Fuzhou Fujian China
Sun Yat-sen University Cancer Center Guangzhou Guandong China
The First Affiliated Hospital of Sun Yat-sen University Guangzhou Guandong China
Harbin Medical University Cancer Hospital Ha'erbin Heilongjiang China
Liaoning Cancer Hospital & Institute Shenyang Liaoning China
The Affiliated Hospital of Qingdao University Qingdao Shandong China
The 2nd Hospital of Xi'An Jiaotong University Xi'an Shanxi China
Tianjin Medical University Cancer Institute & Hospital Tianjin Tianjin China
The First Affiliated Hospital of Zhejiang University school of medicine Hangzhou Zhejiang China
Mayo Clinic, Jacksonville Jacksonville FL USA
The Affiliated Hospital of Nanjing University Medical School Nanjing Jiangsu China
 


A Study of the C-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced And/​or Metastatic Solid Tumors Known to Express C-Kit
Phase:  1
Category:   cKIT Antibody Drug Conjugate
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
NEXT Virginia Fairfax VA USA
MD Anderson Cancer Center Houston TX USA
 


Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Phase:  1/2
Category:   PRMT5 Inhibitor
Conditions:  Solid Tumors

Site
City
State
Country
Dana Farber Cancer Institute Boston MA USA
Memorial Sloan Kettering New York NY USA
Mayo Clinic Cancer Center Phoenix AZ USA
Mayo Clinic, Jacksonville Jacksonville FL USA
Mayo Clinic, Rochester Rochester MN USA
MD Anderson Cancer Center Houston TX USA
South Texas Accelerated Research Therapeutics (START) San Antonio TX USA
Virginia Cancer Specialists Fairfax VA USA
Medical College of Wisconsin Milwaukee WI USA
Sarah Cannon Research Institute Nashville TN USA
Sarah Cannon Research Institute HealthOne Location Denver CO USA
Sarah Cannon Research Institute at Florida Orlando FL USA
New York Cancer and Blood Specialists Oncology Port Jefferson NY USA
Oncology Consultants - Clinical Research Houston TX USA
 


21 trials found